CCM
PLX icon

Consonance Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Consonance Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-564,375
Closed -$10M – 29
2015
Q1 		$10M Buy
564,375
+56,641
+11% +$1.11M 0.91% 21
2014
Q4 		$9.34M Buy
507,734
+5,000
+1% +$107K 1.2% 18
2014
Q3 		$12.2M Buy
+502,734
New +$14.5M 1.67% 21

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Consonance Capital Management's PLX Position: Q2 2015 in Review

Consonance Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2015, closing a stake of 564,375 shares — an estimated $10M sold.

Consonance Capital Management first reported a position in PLX in Q3 2014 and held it in 3 quarters. The position peaked at $12.2M in Q3 2014. 35 funds tracked by Wall St. Rank hold PLX as of Q2 2015.

  • Consonance Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2015 after selling out during the quarter.
  • Consonance Capital Management sold 564,375 Protalix BioTherapeutics shares in Q2 2015, an estimated $10M.
  • Consonance Capital Management first reported a position in Protalix BioTherapeutics in Q3 2014 and held it in 3 quarters.
  • Consonance Capital Management's Protalix BioTherapeutics position peaked at $12.2M in Q3 2014.
  • 35 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2015.

Based on Consonance Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.